Key Highlights
- ARKQ ETF divested 50,312 Rocket Lab shares valued at approximately $4 million on April 27
- The transaction marks ARK’s second major Rocket Lab exit following the prior Friday’s sale of 113,000+ shares
- ARK purchased 263,848 Intellia Therapeutics shares totaling roughly $3.6 million via ARKK and ARKG funds
- The firm also liquidated 13,806 Iridium Communications shares for approximately $538,000
- Rocket Lab shares gained 3.28% Monday, finishing at $82.29 despite ARK’s divestment
Cathie Wood’s investment firm ARK Invest executed multiple portfolio adjustments on Monday, April 27, 2026, based on the company’s published daily trading activity.
The most significant transaction involved offloading 50,312 shares of Rocket Lab via the ARKQ ETF, representing approximately $4.01 million in value. This divestment occurred mere days following ARK’s disposal of more than 113,000 shares of the aerospace stock on the preceding Friday.
The consecutive selling activity within such a compressed timeframe indicates ARK is strategically reducing its exposure to the space technology enterprise.
The timing proves particularly noteworthy given that Rocket Lab’s stock actually climbed 3.28% during Monday’s session, settling at $82.29. Rather than selling during a downturn, ARK capitalized on upward momentum.
The investment firm seems to be locking in gains before Rocket Lab releases its first quarter 2026 financial results, set for disclosure on May 7, 2026.
Financial analysts covering the company anticipate Rocket Lab will post quarterly revenues reaching $189.65 million, representing a 55% year-over-year increase. Projections also call for a loss of $0.07 per share, showing improvement compared to the $0.12 per share loss recorded in last year’s corresponding quarter.
ARK Increases Intellia Therapeutics Position
As ARK reduced its Rocket Lab exposure, the firm simultaneously accumulated shares of Intellia Therapeutics. The transaction involved purchasing 263,848 shares distributed between ARKK and ARKG ETFs, valued at approximately $3.6 million.
Intellia specializes in gene-editing technology, and its shares had declined 4.33% during the trading session. ARK seemingly leveraged this price decline as an entry point.
This behavior aligns with ARK’s established investment approach, frequently increasing positions when stocks the firm considers long-term growth opportunities experience temporary setbacks.
Additionally, ARK disposed of 13,806 shares of Iridium Communications through ARKX ETF, totaling roughly $538,000. This sale extends a developing pattern — ARK previously sold 33,315 Iridium shares the prior Friday and 81,422 shares the Monday preceding that.
Wall Street Perspective on Rocket Lab
Despite ARK’s ongoing divestment, at least one equity analyst maintains positive sentiment toward Rocket Lab.
Stifel analyst Erik Rasmussen elevated his price objective for the stock to $105 from $90 while maintaining a Buy recommendation. His rationale highlighted consistent revenue expansion, a robust project pipeline, and the anticipated debut of the Neutron rocket system later in 2026.
Data from TipRanks indicates Rocket Lab presently carries a Moderate Buy consensus among analysts, derived from nine Buy recommendations and four Hold ratings issued within the last three months.
The consensus price target among analysts stands at $89.00, suggesting potential upside of approximately 8% from present trading levels.
ARK’s subsequent daily trading disclosure will reveal whether the firm continued trimming its Rocket Lab stake during Tuesday’s trading session.
